Levosalbutamol/ipratropium inhalation solution - Arrow International Limited/Sunovion

Drug Profile

Levosalbutamol/ipratropium inhalation solution - Arrow International Limited/Sunovion

Alternative Names: Levalbuterol/ipratropium; Xopenex I.S. + ipratropium; Xopenex IS + ipratropium; Xopenex® + ipratropium inhalation solution

Latest Information Update: 01 Sep 2015

Price : $50

At a glance

  • Originator Arrow International
  • Class Antiasthmatics; Atropine derivatives; Bronchodilators; Ethanolamines; Phenethylamines
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 12 Oct 2010 Sepracor is now called Sunovion Pharmaceuticals
  • 20 Oct 2009 Sepracor has been acquired by Dainippon Sumitomo Pharma
  • 30 Apr 2008 Phase-II clinical trials in Chronic obstructive pulmonary disease in Europe (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top